anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Epinastine
Trial phase: Phase 4
ATC code: R06AX24 | S01GX10
SMILES: NC1=NCC2c3ccccc3Cc3ccccc3N12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: 1 drop each eye for 2 days
Eligibility criteria:
Inclusion Criteria:

Documented history of ocular allergy to cats.
Positive skin prick allergen reaction to cat dander.

Exclusion Criteria:

Use of any topical or systemic corticosteroids, immunosuppressive agents, antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to enrollment into the study.
History of severe asthma, reactive airway disease or bronchial obstruction.
Ocular surgery or trauma in the last year.
Intervention: Olopatadine Hydrochloride
Trial phase: Phase 4
SMILES: CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: 1 drop each eye for 1 day
Eligibility criteria:
Inclusion Criteria:

Documented history of ocular allergy to cats.
Positive skin prick allergen reaction to cat dander.

Exclusion Criteria:

Use of any topical or systemic corticosteroids, immunosuppressive agents, antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to enrollment into the study.
History of severe asthma, reactive airway disease or bronchial obstruction.
Ocular surgery or trauma in the last year.
Intervention: Selegiline
Trial phase: Phase 4
ATC code: N04BD01
SMILES: C#CCN(C)[C@H](C)Cc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.

EmSam : Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
Eligibility criteria:
Inclusion Criteria:

Ages 18 - 65
DSM-IV Bipolar Disorder (I, II, NOS), Depressed Phase
DSM-IV Bipolar Disorder (I,II, NOS), Mixed state with adequate mood stabilization (ie, resolution of manic or hypomanic symptoms for 8 weeks with a minimum of 4 weeks on a stable dose of mood-stabilizing medication that will be continued through all phases of the study).
Prior failure of or inability to tolerate at least one other antidepressant treatment
Physically healthy
Agrees to participate in the study
HAM-D 24 > 10

Exclusion Criteria:

Bipolar Disorder (I, II, NOS), Mixed State without adequate mood stabilization
Prior significant adverse reaction to EmSam
Unstable medical disorder
History of epilepsy (febrile seizure o.k.)
Current use of any medication that might interact with EnSam.
Use within 2 weeks of other antidepressant medication (6 weeks for fluoxetine)
Inability to adhere to a tyramine-free diet
Recent (past 6 months) suicide attempt
Serious suicidal ideation
Pregnant
Breast feeding
Fecund, sexually active females, without adequate contraception
Prior failure to respond to 2 or more adequate oral MAOI trials (2/3 PDR maximum dose, minimum 4 weeks)
Non-nicotine substance abuse/dependence within the past 6 months (1 year for amphetamines/cocaine)
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 99
Group description: Propofol: IV, single bolus at completion of anesthetic, 0.1 ml/kg
Eligibility criteria:
Inclusion Criteria:

Age: 12 months to 6 years old
Planned surgery/procedure: The goal is to enroll patients who will not have pain when they awake from anesthesia. We will include patients who are having magnetic resonance imaging (MRI) under anesthesia, or an eye exam under anesthesia. We will also include those patients who are having a surgery in which a regional or caudal block is part of the planned anesthetic. This will be small orthopedic procedures in the lower extremities; or urologic or general surgical procedures below the level of the umbilicus. These patients have been chosen because the regional/caudal block should result in the patient not having pain when they awake from anesthesia.

(The caudal block is a single epidural injection of local anesthetic that is done when the pediatric patient is under general anesthesia. It is a routine procedure that results in numbness below the level of the umbilicus, and gives relief of pain, for about 8 hours.)

Examples of orthopedic surgeries include, but are not limited to:

Removal of an extra digit or syndactyly repair Club foot releases Lower extremity tendon releases or lengthenings Lower extremity tendon transfers Removal of hardware

Examples of urologic surgeries include, but are not limited to:

Circumcision or circumcision revision hypospadias repair Chordee repair Orchiopexy Orchiectomy

Examples of general pediatric surgeries include, but are not limited to:

Inguinal hernia repair Rectal muscle biopsies Excision of lower extremity or lower abdominal mass Burn scar releases and skin grafting

Exclusion Criteria:

Obstructive sleep apnea-Patients with sleep apnea are not ideal candidates for removal of their endotracheal tube or laryngeal mask airway while still somewhat anesthetized. It is preferable to extubate these patients awake.
Developmental delays-Patients with developmental delays may not interact with their environment, make eye contact, have purposeful actions, or be aware of their surroundings even when at their baseline pre-operatively. It would be difficult to evaluate these features of emergence agitation in children who demonstrate this behavior on a routine basis.
Psychological disorders-Patients with psychological disorders may have the same issues as those with developmental delays when it comes to evaluating their behavior after anesthesia.
Egg white allergy-Propofol is contraindicated in patients with egg white allergies due to risk of allergy to the propofol lecithin base.
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 99
Group description: No propofol
Eligibility criteria:
Inclusion Criteria:

Age: 12 months to 6 years old
Planned surgery/procedure: The goal is to enroll patients who will not have pain when they awake from anesthesia. We will include patients who are having magnetic resonance imaging (MRI) under anesthesia, or an eye exam under anesthesia. We will also include those patients who are having a surgery in which a regional or caudal block is part of the planned anesthetic. This will be small orthopedic procedures in the lower extremities; or urologic or general surgical procedures below the level of the umbilicus. These patients have been chosen because the regional/caudal block should result in the patient not having pain when they awake from anesthesia.

(The caudal block is a single epidural injection of local anesthetic that is done when the pediatric patient is under general anesthesia. It is a routine procedure that results in numbness below the level of the umbilicus, and gives relief of pain, for about 8 hours.)

Examples of orthopedic surgeries include, but are not limited to:

Removal of an extra digit or syndactyly repair Club foot releases Lower extremity tendon releases or lengthenings Lower extremity tendon transfers Removal of hardware

Examples of urologic surgeries include, but are not limited to:

Circumcision or circumcision revision hypospadias repair Chordee repair Orchiopexy Orchiectomy

Examples of general pediatric surgeries include, but are not limited to:

Inguinal hernia repair Rectal muscle biopsies Excision of lower extremity or lower abdominal mass Burn scar releases and skin grafting

Exclusion Criteria:

Obstructive sleep apnea-Patients with sleep apnea are not ideal candidates for removal of their endotracheal tube or laryngeal mask airway while still somewhat anesthetized. It is preferable to extubate these patients awake.
Developmental delays-Patients with developmental delays may not interact with their environment, make eye contact, have purposeful actions, or be aware of their surroundings even when at their baseline pre-operatively. It would be difficult to evaluate these features of emergence agitation in children who demonstrate this behavior on a routine basis.
Psychological disorders-Patients with psychological disorders may have the same issues as those with developmental delays when it comes to evaluating their behavior after anesthesia.
Egg white allergy-Propofol is contraindicated in patients with egg white allergies due to risk of allergy to the propofol lecithin base.
Intervention: Ertapenem
Trial phase: Phase 4
ATC code: J01DH03
SMILES: [H][C@@]1(SC2=C(C(=O)O)N3C(=O)[C@]([H])([C@@H](C)O)[C@@]3([H])[C@H]2C)CN[C@]([H])(C(=O)Nc2cccc(C(=O)O)c2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Administration of 1 gram ertapenem I.V.

Ertapenem: powder for infusion, 1 gram I.V., single dose over 30 min.
Eligibility criteria:
Inclusion Criteria:

Hospitalized patients 18 years or older requiring elective surgical intervention (open or laparoscopic surgery) at the colon will be eligible for this study.
Patients with benignant disorders (e.g. colonic diverticulosis) will be preferred.

Exclusion Criteria:

Pregnancy or lactation in women
Emergency surgery, history of serious allergy or intolerance to β-lactam antibiotics and other carbapenems
Systemic antimicrobial therapy with ceftazidime (internal standard of high-performance liquid chromatography / mass spectrometry) within a 7 days period prior to study entry
Ongoing intraabdominal infections
Terminal illness
Chronic immunosuppressive therapy
Severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST > 6 x upper limit of normal (ULN) and bilirubin > 3 x ULN, severe renal insufficiency with a creatinine clearance ≤30 mL/min., neutrophil count < 1000 cells/mm3, platelets < 75000 cells/mm3 and coagulation studies (INR) > 1.5 x ULN, ongoing therapy with valproin acid.
Intervention: Budesonide
Trial phase: Phase 3
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 243
Group description: Pulmicort Turbuhaler
Eligibility criteria:
Inclusion Criteria:

Asthma clinically diagnosed since at least 6 months.
Lung function values measured ≥ 50% and ≤ 90% of predicted normal.
Patients with reversible airway obstruction Daily use of inhaled steroids (any brand) for >3 months.

Exclusion Criteria:

Use of oral, rectal or parenteral steroids within 30 days prior to start of study.
Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to start of randomised treatment.
Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.
Intervention: ASPARTIC ACID
Trial phase: Not Applicable
SMILES: N[C@@H](CC(=O)O)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 55
Group description: Patients receive 6 doses of Erwinia asparaginase (dosage 25,000 IU/m2 intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.

pharmacological study : Correlative studies

laboratory biomarker analysis : Correlative studies

asparaginase : Given IM
Eligibility criteria:
Inclusion Criteria:

Diagnosis of acute lymphoblastic leukemia

Concurrently enrolled on a frontline Children's Oncology Group treatment trial (i.e., COG-AALL0232 or COG-AALL0531, COG-AALL0331, or COG-AALL0434) at a participating institution

Must have 1 or more courses of asparaginase remaining to be administered on the treatment protocol
Must have had a grade ? 2 hypersensitivity reaction to PEG-asparaginase
No history of pancreatitis ? grade 2
No prior Erwinia asparaginase
Intervention: Novolog mix 70/30
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 160
Group description: Subjects received individually adjusted dose of biphasic insulin aspart 30 (BIAsp 30) once daily for 16 weeks. If the treatment target of HbA1c below 7% was reached after 16 weeks of treatment, the subject continued the reached dose until week 48 (end of trial). If the treatment target of HbA1c below 7% was not achieved at week 16, then BIAsp 30 treatment was increased to twice daily for additional 16 weeks. If the treatment target of HbA1c below 7% was reached after 32 weeks of treatment, the subject continued the reached dose until week 48 (end of trial). If the treatment target of HbA1c below 7% was not achieved at week 32, then BIAsp 30 treatment was increased to three times daily for additional 16 weeks until week 48 (end of trial).
Eligibility criteria:
Inclusion Criteria:

Type 2 Diabetes Mellitus for more than 12 months
HbA1c: 7.5 - 11.0%
An antidiabetic regimen that has been stable for at least 3 months prior to screening
An antidiabetic regimen that includes a minimum of 2 oral anti-diabetic drugs (OADs) or 1 OAD plus evening or bedtime basal insulin
OADs dosed at 50% or more of the maximum recommended dose

Exclusion Criteria:

Use of any insulin preparations other than NPH or glargine within the past 6 months
Use of more than 60 units of insulin per day
Morning time insulin administration
Use of more than one insulin dose daily
Intervention: Sibutramine
Trial phase: Phase 4
ATC code: A08AA10
SMILES: CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 26
Group description: Sibutramine 15 mg daily

Sibutramine: 15 mg daily
Eligibility criteria:
Inclusion Criteria:

Obese (BMI >= 30)

Exclusion Criteria:

Medication regimen that represents medical contraindication to sibutramine
Serious unstable or uncontrolled medical conditions that represent contraindication to sibutramine
Pregnancy
Intervention: Paricalcitol
Trial phase: Phase 4
ATC code: H05BX02
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)/C=C/[C@H](C)C(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Paricalcitol (ABT-358 Zemplar) Injection was administered to participants on hemodialysis.
Eligibility criteria:
Inclusion Criteria:

Patients >=18 years with secondary hyperparathyroidism (iPTH >= 300 pg/mL)
Patients in a chronic hemodialysis or peritoneal dialysis program previously treated with vitamin D metabolites or without previous treatment
Patients in which treatment with paricalcitol injection or oral is clinically indicated according to the criteria of the participating investigator
Patients providing their signed informed consent to participate in the trial

Exclusion Criteria:

Patients with severe hyperparathyroidism (iPTH > 3,000 pg/ml)
Patients with hypercalcaemia (calcium >=11.0 mg/dl, adjusted according to Albumin level), hyperphosphataemia (phosphorus >= 6.5 mg/dl) or patients with calcium x phosphorus >= 70
Known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients
Patients who have participated in clinical studies within the last month or who are currently enrolled in clinical studies
Patients who cannot tolerate or take phosphorus binders that do not contain Calcium and/or Aluminum
Patients that in the opinion of the investigator, for any reason, are not good candidates for therapy with Synthetic Analogues of Vitamin D
Intervention: Mitomycin
Trial phase: Phase 4
ATC code: L01DC03
SMILES: [H][C@]12N[C@@]1([H])CN1C3=C(C(=O)C(N)=C(C)C3=O)[C@@H](COC(N)=O)[C@]12OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Application of Mitomycin-C in trabeculectomy to reduce super-scarring.
Eligibility criteria:
Inclusion Criteria:

Open angle glaucoma
Maxima anti-glaucoma medication failed
Age>18
Able to complete the follow up

Exclusion Criteria:

Topical eye inflammation
Angle closure glaucoma
Deformity glaucoma
One eye glaucoma
Previous conjunctiva opened
Allergy to collagen
Intervention: Ziprasidone
Trial phase: Not Applicable
ATC code: N05AE04
SMILES: O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Subjects switch to ziprasidone from current antipsychotic(s)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder
BMI>29.9 or family history of diabetes and/or abdominal circumference greater than 88 cm in women or 102 cm in men
Pre-diabetic oral glucose tolerance test
Current treatment with olanzapine, risperidone, paliperidone, or quetiapine, or combination of these
Willing to switch to ziprasidone
No psychiatric hospitalizations in past three months and judged by treating clinician to be suitable for antipsychotic medication switch
Able to give informed consent to study

Exclusion Criteria:

Judged to be currently suicidal, homicidal, or unable to cooperate with treatment
Unstable serious medical illness
Current use of drugs that interfere with glucose and fat metabolism (sulfonylureas, metformin, thiazolidinediones). The use of "statins" and fibrates will be allowed ONLY if stable dose for past 3 months.
Current diagnosis of diabetes
Fasting blood glucose >125 mg/dl
Intervention: Zolpidem
Trial phase: Phase 2
ATC code: N05CF02
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 10
Group description: medication dosed at 2200 and 0200 per feeding tube

zolipidem: dosed at 2200 and 0200 per feeding tube
Eligibility criteria:
Inclusion Criteria:

Burn injury > 20% total body surface area
Between 3 and 18 years of age
< 7 days from acute injury
Written informed consent and HIPPA release signed

Exclusion Criteria:

Suspected anoxic brain injury or head injury
Hepatic or endocrine disease
History of alcoholism or substance abuse
Pre-existing neurological or primary psychiatric disorder
Medical history of pre-existing sleep disorder or lactose deficiency
Questionable survival (<72 hrs) as decided by PI
Receipt of drugs with known effects on sleep within 24 hrs of study entry
No informed consent/HIPPA release
Intervention: Ramelteon
Trial phase: Phase 2
ATC code: N05CH02
SMILES: CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 10
Group description: dosed at 2200 and 0200 per the feeding tube

ramelteon: medication dosed at 2200 and 0200 per feeding tube
Eligibility criteria:
Inclusion Criteria:

Burn injury > 20% total body surface area
Between 3 and 18 years of age
< 7 days from acute injury
Written informed consent and HIPPA release signed

Exclusion Criteria:

Suspected anoxic brain injury or head injury
Hepatic or endocrine disease
History of alcoholism or substance abuse
Pre-existing neurological or primary psychiatric disorder
Medical history of pre-existing sleep disorder or lactose deficiency
Questionable survival (<72 hrs) as decided by PI
Receipt of drugs with known effects on sleep within 24 hrs of study entry
No informed consent/HIPPA release
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment

N-Acetylcysteine : 3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
Eligibility criteria:
Inclusion Criteria:

Borderline Personality Disorder, as assessed by SCID-II
A score of 10 or greater on the Self Harm Inventory (SHI) at time of evaluation
Ability to give informed consent
agreement to engage in a reliable form of birth control (women only)

Exclusion Criteria:

primary diagnosis of a psychotic disorder
active substance abuse or dependence
unstable medical condition
History of intolerance/allergic reaction to N-Acetylcysteine
pregnancy, breastfeeding, or intent to become pregnant during study
Inability to understand English
Cognitive Impairment
Intervention: Meglumine gadobenate
Trial phase: Not Applicable
ATC code: V08CA08
SMILES: CNCC(O)C(O)C(O)C(O)CO.CNCC(O)C(O)C(O)C(O)CO.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])C(COCc1ccccc1)C(=O)[O-].[Gd+3].[H+].[H+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study

gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
Eligibility criteria:
Inclusion Criteria:

Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
International Normalized Ratio (INR) <1.4
Platelet count > 80,000

Exclusion Criteria:

Contraindications to TACE procedure
Unable to have an MRI Scan
Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min)
Pregnancy
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment

N-Acetylcysteine : 3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
Eligibility criteria:
Inclusion Criteria:

DSM-IV diagnosis of OCD, confirmed by SCID-IV; symptoms of at least 1 year duration
moderate to severe OCD symptoms (Y-BOCS > 16)
documented failure of an adequate trial of an SSRI
agreement to engage in a reliable form of birth control (women only)

Exclusion Criteria:

primary diagnosis of a psychotic disorder
active substance abuse or dependence
unstable medical condition
prior exposure to N-Acetylcysteine
prior psychosurgery
pregnancy, breastfeeding, or intent to become pregnant during study
liver function tests (LFTs) elevated to more than 2x the upper limit of normal
evidence of active liver disease
seizure disorder
active suicidal ideation